biotech sector rally
Biotech Sector Snapshot: Trial Failure Meets a Rally
One failed trial erased more than a billion dollars from a single biotech’s market value this week. The sector it trades in barely noticed. Both of those facts are true at the same time, and untangling why is more useful than picking a single winner to write about. The Rally’s Math: XBI Up 36% Even…
RenovoRx Hits 52-Week High as Revenue and Trial News Align
RenovoRx spent August checking boxes most microcap biotechs take years to check. A pivotal trial finished enrolling. Quarterly revenue kept climbing. A Nasdaq compliance problem got resolved. By month’s end, the stock was sitting at a 52-week high. RenovoRx Hits 52-Week High as Revenue Growth and Trial Enrollment Both Deliver RenovoRx (Nasdaq: RNXT) shares rose…
Capricor Gains 11% as FDA Pushes Deramiocel Decision to Nov
A three-month delay is not usually something a stock rallies on. Capricor Therapeutics gained 11% anyway. The company’s Duchenne muscular dystrophy therapy just got a longer FDA review instead of a decision, and investors treated the extra scrutiny as a sign the door stayed open rather than a rejection in slow motion. Capricor Gains 11%…
